An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Diacerein (Primary)
- Indications Epidermolysis bullosa
- Focus Registrational; Therapeutic Use
- Acronyms EBShield Study
- Sponsors TWi Biotechnology
Most Recent Events
- 30 May 2025 Planned End Date changed from 1 Mar 2026 to 1 Jan 2027.
- 30 May 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Mar 2026.
- 07 Feb 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2023 to 1 Feb 2024.